Loading organizations...
Sanquinnovate serves as the commercialization arm for Sanquin's scientific research and intellectual property, translating discoveries in hematology, immunology, and oncology into viable products and services. It utilizes Sanquin's deep expertise in blood science to develop innovative solutions for clinical and industrial applications.
Established by Sanquin, the Dutch blood supply organization, Sanquinnovate was founded on the insight that its extensive research required a dedicated pathway to market. This initiative formalizes the process of transforming foundational scientific breakthroughs into practical advancements, ensuring valuable innovations move beyond academic discovery.
Its offerings target pharmaceutical companies, biotech firms, and healthcare providers seeking advanced diagnostic and therapeutic solutions. Sanquinnovate's vision is to maximize the societal impact of Sanquin’s research by accelerating the availability of novel medical advancements, ultimately improving public health through applied science.
Sanquinnovate has 1 tracked investment across 1 company. The latest tracked deal is $47.5M Other Equity in Xenikos in September 2021.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Sep 8, 2021 | Xenikos | $47.5M Other Equity | Craig A. Collard | Medicxi, Oost NL, RA Capital Management |